US2005182070A1PendingUtilityA1

Method for the treatment of allergic conditions

62
Priority: Mar 15, 1993Filed: Apr 15, 2005Published: Aug 18, 2005
Est. expiryMar 15, 2013(expired)· nominal 20-yr term from priority
Inventors:Jean Gobert
A61P 43/00A61P 37/08A61P 25/20A61P 25/22A61P 29/00C07D 295/088A61P 11/06C07D 295/073C07D 295/26A61K 31/495A61P 17/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method for the treatment of allergic conditions by administering to a patient an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chloro-phenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid. The treatment is conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment of an allergic condition which comprises administering to a patient in need of such treatment an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, said treatment being conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.  
     
     
         2 . A method for the treatment of asthma which comprises administering to a patient in need of such treatment an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, said treatment being conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.  
     
     
         3 . A method for the treatment of inflammation which comprises administering to a patient in need of such treatment an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, said treatment being conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.  
     
     
         4 . A method according to  claim 1  wherein the administration is oral.  
     
     
         5 . A method according to  claim 1  wherein the administration is parenteral.  
     
     
         6 . A method according to  claim 1  wherein the administration is rectal.  
     
     
         7 . A method according to  claim 3  wherein the administration is topical.  
     
     
         8 . A method according to  claim 1  wherein the effective amount is in the range of from 0.5 to 100 mg per day.  
     
     
         9 . A method according to  claim 8  wherein the amount is in the range of from 2 to 20 mg per day.

Join the waitlist — get patent alerts

Track US2005182070A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.